Navigation Links
Baseline characteristics of children with mild persistent asthma predict response to ICS
Date:5/22/2012

ATS 2012, SAN FRANCISCO A further analysis of a previously published National Heart, Lung, and Blood Institute (NHLBI) funded study of children with mild persistent asthma reports the relative benefits of inhaled corticosteroid (ICS) treatment varies among children with differing demographic and clinical characteristics.

"We performed post-hoc data analysis on 288 children enrolled in the TReating Children to Prevent Exacerbations of Asthma (TREXA) study performed by the NHLBI funded Childhood Asthma Research and Education (CARE) Network," said Lynn Gerald, PhD, MSPH, professor in the Department of Health Promotion Sciences and associate dean of research in the College of Public Health at the University of Arizona. "Our findings suggest that all children with mild persistent asthma benefit from ICS treatment, but some groups benefit more than others."

The TREXA trial compared four ICS treatment strategies: daily treatment (daily), daily treatment plus symptom-targeted treatment (combined), symptom-targeted only treatment (rescue), and placebo. Daily treatment, but not combined or rescue treatment, reduced the time to first exacerbation compared with placebo, and all three strategies reduced treatment failures. Time to treatment failure was defined as time to an oral corticosteroid-requiring exacerbation and treatment failure was defined as experiencing two or more oral corticosteroid-requiring exacerbations.

In post-hoc subgroup analyses using either time to first exacerbation or time to treatment failure as an outcome, children in the daily and combined groups who were younger (6-11 yrs versus 12-17 years), were non-Hispanic, had eczema, were skin test positive, and who had IgE levels >185K/uL experienced treatment benefit as compared to those assigned to placebo. Among children assigned to the rescue group, the results were similar to those above when using time to treatment failure as an outcome; however, when using time to first exacerbation as an outcome, only those with eczema, high IgE levels, and less than perfect asthma control during the run-in period were demonstrated to benefit when compared to placebo.

"Our study indicates that some groups of children with mild persistent asthma have greater exacerbation risk than others and therefore have more to gain from ICS treatment for reducing this risk," said Dr. Gerald. "These findings need to be validated in future studies."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Baseline PSA predicts risk of death from prostate cancer
2. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
3. Does baseline concussion testing really reduce risks to athletes?
4. Validity of Baseline Concussion Tests Questioned
5. Concussion baseline important for accurate future assessment in at-risk youth athletes
6. Researchers find that sociodemographic characteristics are related to a patients willingness to participate in cancer screenings
7. Researchers report no difference in breast cancer characteristics after oophorectomy
8. Thesis investigates characteristics of society using sports activities as research tool
9. Why do risks with human characteristics make powerful consumers feel lucky?
10. New study helps clarify symptoms and characteristics of acid reflux in neonates
11. Pain characteristics suggest higher benefit from gallbladder surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... New York (PRWEB) , ... January 24, 2017 , ... ... Brazilian butt lifts is on the rise. According to the American Society of ... since 2000. On average, these procedures are performed every 30 minutes of every day. ...
(Date:1/24/2017)... ... 24, 2017 , ... PeroxyChem Food and Beverage Safety announced ... at the International Production and Processing Expo (IPPE) in Atlanta, Georgia from Jan. ... that is used in poultry processing facilities to provide constant, real-time data that ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups ... of the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and ... The entrepreneurs will showcase their businesses on February 6, 2017, at Under Armour’s ...
(Date:1/24/2017)... ... ... Bellus Medical, a leader in medical aesthetics, today announced that Marek Dobke, M.D., ... will provide physician oversight for in-house clinical studies and hands-on device training, among other ... Professor of Surgery at UC San Diego Health and is a board certified plastic ...
(Date:1/24/2017)... Boston, MA (PRWEB) , ... January 24, 2017 ... ... What They Really Need to Thrive , Well-meaning studies such as the Fordham ... and schools can better serve top students, such as including gifted or high-achieving ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , Jan. 24, 2017   Intrexon Corporation ... and industrialization of biology to improve the quality of life ... entered into a definitive agreement to acquire GenVec, Inc ... pioneer in the development of AdenoVerse™ gene delivery technology.  ... expertise in adenoviral vectors and cGMP drug product manufacturing to ...
(Date:1/24/2017)... 24, 2017   Keneric Healthcare , a ... effective patient care products, today announced their partnership ... the reach of both companies by leveraging their ... Angelini Pharma Inc . ... include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal).  RTD™ ...
(Date:1/24/2017)... 2017 Stock-Callers.com today has issued research ... ZTS ), Mallinckrodt PLC (NYSE: MNK ), ... Inc. (NYSE: DPLO ). According to pharmaceutical manufacturer ... 2017 for the Generic Drugs industry, including a possible reduction ... current growth, and a speedier FDA approval process that could ...
Breaking Medicine Technology: